Abstract
Ponatinib is a bcr-abl tyrosine-kinase inhibitor (TKI) used to treat resistant and refractory chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia that express bcr-abl. Neutrophilic panniculitis has been described in rare cases of patients on other TKIs in the same class as ponatinib. We present the first case of neutrophilic panniculitis following treatment with ponatinib and summarize the other cases of panniculitis caused by TKIs.
Keywords:
chronic myeloid leukemia; drug reaction; panniculitis; ponatinib.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
MeSH terms
-
Female
-
Fusion Proteins, bcr-abl / antagonists & inhibitors*
-
Humans
-
Imidazoles / administration & dosage
-
Imidazoles / adverse effects*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
-
Middle Aged
-
Neutrophils / pathology
-
Panniculitis / chemically induced*
-
Panniculitis / pathology*
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects*
-
Pyridazines / administration & dosage
-
Pyridazines / adverse effects*
Substances
-
Imidazoles
-
Protein Kinase Inhibitors
-
Pyridazines
-
ponatinib
-
Fusion Proteins, bcr-abl